MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Hana TOŠKOVÁ, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Gabriela VAŇKOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Šárka POSPÍŠILOVÁ, Jiří MAYER a Zdeněk RÁČIL. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Leukemia & Lymphoma. London: Informa Healthcare, Gordon and Breach, 2013, roč. 54, č. 9, s. 2083-2087. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.762649. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1163539, author = {Malčíková, Jitka and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Tošková, Hana and Šebejová, Ludmila and Šmardová, Jana and Oltová, Alexandra and Vaňková, Gabriela and Juračková, Lenka and Trbušek, Martin and Pospíšilová, Šárka and Mayer, Jiří and Ráčil, Zdeněk}, article_location = {London}, article_number = {9}, doi = {http://dx.doi.org/10.3109/10428194.2012.762649}, keywords = {BCR-ABL1; T315I; chronic myelogenous leukemia; therapy}, language = {eng}, issn = {1042-8194}, journal = {Leukemia & Lymphoma}, title = {The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.}, url = {http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal}, volume = {54}, year = {2013} }
TY - JOUR ID - 1163539 AU - Malčíková, Jitka - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Tošková, Hana - Šebejová, Ludmila - Šmardová, Jana - Oltová, Alexandra - Vaňková, Gabriela - Juračková, Lenka - Trbušek, Martin - Pospíšilová, Šárka - Mayer, Jiří - Ráčil, Zdeněk PY - 2013 TI - The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. JF - Leukemia & Lymphoma VL - 54 IS - 9 SP - 2083-2087 EP - 2083-2087 PB - Informa Healthcare, Gordon and Breach SN - 10428194 KW - BCR-ABL1 KW - T315I KW - chronic myelogenous leukemia KW - therapy UR - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal L2 - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal N2 - The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. ER -
MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Hana TOŠKOVÁ, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Gabriela VAŇKOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Šárka POSPÍŠILOVÁ, Jiří MAYER a Zdeněk RÁČIL. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, Gordon and Breach, 2013, roč.~54, č.~9, s.~2083-2087. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.762649.
|